Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Monday, May 26th, 2008.

 

Sponsors

Archive for May 26th, 2008

[ILLUSTRATION OMITTED]

New gospel singer DeWayne Woods says he wants to be an artist who says something meaningful in his music.

"Singers come a dime a dozen," he tells JET. "But to be a singer and have something to say in your music I think is absolutely amazing."

Earlier this year, his debut CD, Introducing DeWayne Woods & When Singers Meet won three Stellar Awards: New Artist of the Year, Male Vocalist of the Year, and Urban Inspirational Single/Performance. His tune, Let Go, written by P.J. Morton also won Song of the Year.

Since the Stellar wins, he has a new level of recognition. "People are realizing that there is a voice inside of me, not just a singing voice, but a speaking voice. I sing lyrics that people need to hear, lyrics that are changing lives for people; words that are speaking life into them. People stop me wherever I am and tell me, ‘Let Go saved my life. Let Go changed my life.’"

A native of Kansas City, MO, he was a backup singer for pop superstar Celine Dion and gospel greats Kurt Carr and Karen Clark Sheard. He also is a former member of John P. Kee’s New Life Choir and more recently a member of Donald Lawrence and his Tri-City Singers. Lawrence signed Woods to his label, QuietWater Entertainment, under the Zomba Gospel Group, and co-executive produced the CD.

"I call DeWayne a smooth healer," says Lawrence. "His voice is like silk and there is healing in every note."

A highlight on the 12-song CD is God Still Heals, which he prefaces with a personal testimony about being healed by God of being HIV positive. "Music has a healing virtue in it," Woods says.

He was diagnosed with HIV in 1992 at age 17 and says, "1 went through years of treatment and different diagnoses." By 2000, he was told by a doctor there were no signs of the HIV virus.

Woods notes, "God Still Heals doesn’t have to be about HIV or AIDS or sickness, it can be whatever situation that is ailing you."

COPYRIGHT 2008 Johnson Publishing Co.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

INFORMATION technology is one of those topics many executives don’t care to think about unless they’re forced to, when, for example, the computer doesn’t turn on one morning.

That’s the clientele Thousand Oaks-based Cloudworks is seeking.

While it’s common for companies such as Salesforce.com to host single applications, Cloudworks is one of a few companies that offer a comprehensive IT network online.

It works like this: Employees log on to Cloudworks’ site with a password and get a screen that leads them on to a network. They can send and receive e-mails, write memos, create spreadsheets and build PowerPoint presentations as they would on any Microsoft application. The virtual network is custom-built for that company, and employees access and store information entirely on Cloudworks’ servers.

[ILLUSTRATION OMITTED]

"We’re the IT department," said Mike Eaton, chief executive of Cloudworks. "Instead of having servers down the hall, we take all that away and run everything in our data center. All you need is a Web browser."

The system is saving one client of 300 employees $200,000 a year in IT costs, Eaton said.

Cloudworks automatically upgrades software applications to the latest versions on the market and equips the system with virus protection. Users can also access the network with any mobile device.

Cloudworks is only seven months old, but has about 300 clients. That’s because its consulting division, Atticus, has been around for 11 years. The bootstrapped company has about 25 employees.

Staff reporter Booyeon Lee can be reached at blee@labusinessjournal.com or at (323) 5495225, ext. 230.

COPYRIGHT 2008 CBJ, L.P.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

According to news.gov.hk: A three-year-old boy with encephalitis has died, the Centre for Health Protection says. He had an underlying medical condition and developed fever and a rash over his hands and feet on May 22. He was admitted to United Christian Hospital in a deteriorating condition on May 24 and died today. Lab tests show he hadrespiratory …

Read the rest of this article with a Free Trial at HighBeam Research.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

AMSTERDAM, The Netherlands, May 26 /PRNewswire-FirstCall/ — - Production Increase Brings Large Disease Areas within Reach

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a Cooperative Research and Development Agreement from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Bethesda, Maryland, that promises to substantially enhance the power of AMT’s gene therapy platform.

The Agreement

The Cooperative Research and Development Agreement (CRADA) with the NIH gives AMT the option to license the exclusive rights to the recombinant adeno-associated virus (rAAV) baculoviral manufacturing technology developed for treating Duchenne Muscular Dystrophy (DMD) by Robert Kotin, Ph.D., and colleagues at the NHLBI Laboratory of Biochemical Genetics. While AMT’s current production platform is based on a 50-liter bioreactor set-up, the application of the NIH technology has been scaled-up to 250 liters, and allows for further expansion to 1,000 liters. These production levels are unique in the gene therapy field today and are relevant in the context of some of the products that AMT has under development that affect large patient populations, such as Factor IX for hemophilia B, IGF-I for liver cirrhosis, and AMT-011 for NASH. The scale-up is also important for treatment of Duchenne Muscular Dystrophy (DMD) for which AMT has just closed an agreement with La Sapienza University in Rome, Italy, since this indication requires a relatively high dose of gene therapy vector in order to correct the defect in all affected muscles.

Ronald Lorijn, CEO of AMT said: "This CRADA with the NIH provides AMT with a technology that in combination with our proprietary in-house platform adds a whole new dimension to our manufacturing platform. Our combined effort has the potential to greatly increase the therapeutic reach of our gene therapies to benefit far larger patient groups than was hitherto thought possible. In addition, it would allow us to attempt the treatment of diseases that require the systemic (as opposed to local) expression of therapeutic genes. Duchenne Muscular Dystrophy is such a disease, and together with La Sapienza in Rome we will work very hard to develop a treatment for this wasting disorder for which there is currently no treatment."

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT’s proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business, including, but not limited to, the timely commencement and success of AMT’s clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT’s products, effectiveness of AMT’s marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT’s initial public offering on June 20, 2007, and AMT’s public announcements made from time to time.

CONTACT: For information: Andre Verwei, CFO, +31-20-566-5686, a.verwei@amtbiopharma.com; Rob Janssen, Director Corporate Communications & Investor Relations, +31-20-566-7509, r.janssen@amtbiopharma.com

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

More than 78 companies nationwide fired an employee in the past year for e-mail policy violations, according to a recent survey of 301 companies nationwide with 1,000 or more employees.

The study of outgoing e-mail and content security in the workplace found that 69 said their business was affected by the exposure of sensitive or embarrassing information in the past year. The study was performed by Proofpoint, a Sunnyvale, Calif.-based firm that provides e-mail security and data loss prevention to defend against inbound threats such as spam and viruses, prevent leaks of confidential information and encrypt sensitive e-mails.

Of the 301 businesses that responded, 114 companies perform regular audits of outbound e-mail content, 36 investigated the exposure of confidential, sensitive or private information via a posting to a social networking site and 102 had e-mail subpoenaed.

GCR building system for mariners union

Seafarers International Union has selected New Orleans-based GCR and Associates to create an enterprise data management system to support its membership and associate companies.

“This is an incredible pivotal project for our firm,” said Greg Rigamer, CEO of GCR and Associates. “It puts us in the midst of a major international organization for the management of their personnel and their assets.”

This system will build on Seafarers’ existing business processes and technology infrastructure for managing Seafarers’ data such as individual membership, training and certifications, pension checks, dues collection, benefit plan status and other union-related functions.

The system will specifically solve challenges Seafarers is experiencing because of increasing member services online.

Seafarers International Union represents unlicensed U.S. merchant mariners sailing aboard U.S.-flag vessels in the deep sea, Great Lakes and inland trades.

Rigamer said GCR, which works mostly with airports, is beginning to do more with the maritime industry and hopes the Seafarers project will strengthen that connection.

City seeks transparency, ease in new Web site

The city of New Orleans has redesigned its Web site in an effort to make recovery information more accessible and governmental interaction easier.

“Citizens, businesses and visitors will find the new site is easier to navigate,” said Anthony Jones, interim director of the Mayor’s Office of Technology.

Citizens and visitors can view the new site at www.cityofno.com and complete a survey to offer feedback to help determine if the site meets users’ needs.

The new site also is also designed to provide faster and easier interaction with city government departments, according to the city.

“The redevelopment of the city’s Web site increases access to vital information, increases the number of services offered to citizens, creates greater transparency and offers streamlined payment processes for government services,” Mayor C. Ray Nagin said.

Study: Feds limiting online access to records

Most federal agencies do not comply with 1997 language in the Freedom of Information Act requiring them to expand online access to records, according to a 2007 study by the National Security Archive at George Washington University.

Only 21 percent of agencies post on their Web sites the four categories of information required by amendments to FOIA a decade after they became law. The four required categories are agency opinions and orders, policy statements, frequently requested records and guidance to agency staff.

Only 6 percent were found to post all 10 types of information deemed essential under FOIA. These include information about where to send requests, fee status, fee waivers, expedited processing, reply time, exemptions, administrative appeal rights, where to send appeals, judicial review rights and an index of records of major information systems.

Just 26 percent of agencies provide online forms for FOIA requests, according to the study.

The study also found that many agency Web links were either missing or incorrect.

Copyright 2008 Dolan Media Newswires
Provided by ProQuest Information and Learning Company. All rights Reserved.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

CHICAGO (AFP) — Some strains of bird flu are coming ever closer to developing the traits they need to cause a human pandemic, a study released Monday said.

Researchers who analysed samples of recent avian flu viruses found that a few H7 strains of the virus that have caused minor, untransmissible infections in people in North America between 2002 and 2004 have increased their affinity for the sugars found on human tracheal cells.

Subsequent tests in ferrets suggested that these viral strains were not readily transmissible.

But one strain of the H7N2 virus, a low pathogenic avian flu strain isolated from a man in New York in 2003, replicated in the ferret’s respiratory tract and was passed between infected and uninfected ferrets suggesting it could be transmissible in humans. …


Read the full article with a Free Trial at MyWire.

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis